Advanced differentiated thyroid cancer: when to stop radioiodine?.
Citation: The Quarterly Journal of Nuclear Medicine. 63(3):267-270, 2019 Sep.PMID: 31271271Institution: MedStar Washington Hospital CenterDepartment: Medicine/Nuclear MedicineForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Iodine Radioisotopes/tu [Therapeutic Use] | *Thyroid Neoplasms/pa [Pathology] | *Thyroid Neoplasms/rt [Radiotherapy] | Disease Progression | Humans | Treatment OutcomeYear: 2019ISSN:- 1824-4785
Item type | Current library | Collection | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|---|
Journal Article | MedStar Authors Catalog | Article | 31271271 | Available | 31271271 |
Radioiodine (RAI) is a pivotal important treatment for patients with metastatic differentiated thyroid cancer (DTC). In order to determine when a patient will no longer respond to RAI, multiple classifications have been described to categorize a patient as radioiodine refractory (RAI-R). Current classifications, although very useful, are problematic and controversial and cannot be merely applied in the context of individualized patient management. In addition, classifications on how to define RAI-R disease are continuosly evolving as more studies are published and managing physicians better understand the limitations and confounding factors of present classifications. Accordingly, each patient should be individually managed with a good understanding of the limitations of the various classifications, assessing the many other factors that affect the patient's specific clinical situation and delivering appropriate individualized patient care.
English